ClinicalTrials.gg
CompletedNCT04966338Updated Oct 18, 2022

Efficacy and Safety of Xacrel® (Ocrelizumab) in Participants With Relapsing Remitting Multiple Sclerosis

A Phase 3 interventional study of Ocrelizumab (CinnaGen, Iran) and Ocrelizumab (Roche, Switzerland) in Multiple Sclerosis and Relapsing-Remitting, sponsored by Cinnagen. Completed at 15 sites in Iran, Islamic Republic of. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2022-10-18.

Sponsored by Cinnagen · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 10 months after the study started (first participant enrolled Aug 2019, registered Jun 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
170
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing ocrelizumab in Multiple Sclerosis — 3 open to participants now, 14 under way, 8 of them phase 3. ocrelizumab · Multiple Sclerosis.

Enrollment
14th of 27
170 · median 170
Started
2019
with 2 others
Phase 3
13 of 27
2 open now
Registered
16th of 27
by date
Lead sponsor
1 of 27
Cinnagen

Among the 27 studies testing ocrelizumab in Multiple Sclerosis, this one is the 14th largest by enrollment, is one of 3 that started in 2019, is one of 13 in phase 3, and was the 16th registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

3 of the 27 studies testing ocrelizumab in Multiple Sclerosis are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ocrelizumab

ocrelizumab: first FDA approval 2017 (OCREVUS), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing ocrelizumab in Multiple Sclerosis, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of Ocrelizumab produced by CinnaGen compared with Ocrevus® (Roche, Switzerland) in subjects with relapsing remitting multiple sclerosis (RRMS).

All the participants will receive one of the following regimens:

Ocrelizumab (CinnaGen) or Ocrevus® (Roche, Switzerland) ,600 mg (given as dual infusions of ocrelizumab 300 mg on Days 1 and 15 of the first 24-week treatment cycle and as single infusions of 600 mg on Day 1 for each 24-week treatment cycle, thereafter) every 24 weeks.

The primary objective of this study is to verify the equivalency of Ocrelizumab (CinnaGen) versus Ocrevus® (Roche, Switzerland) in reducing the annualized relapse rate (ARR) in participants with relapsing remitting multiple sclerosis (RRMS) at 2 years.

03

Conditions studied

  • Multiple Sclerosis
  • Relapsing-Remitting

Browse trials for

Keywords

  • RRMS
  • Annualized Relapse Rate
  • Monoclonal
  • Humanized
  • Ocrelizumab
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability to provide written, and to be compliant with the schedule of protocol assessments.
  2. Ages 18-55 years at screening, inclusive.
  3. Diagnosis of MS, in accordance with the revised McDonald criteria (2010).
  4. At least two relapses having occurred within the past 2 years or one relapse within the past 12 months prior to screening.
  5. Neurological stability for ≥ 30 days prior to both screening and baseline.
  6. EDSS, at screening, from 0 to 5.5 inclusive.
  7. Patients of must use reliable means of .

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of primary progressive MS.
  2. Disease duration of more than 10 years in patients with an EDSS ≤ 2.0 at screening.
  3. Inability to complete an MRI ( for MRI include but are not restricted to claustrophobia, weight ≥ 140 kg, pacemaker, cochlear implants, presence of foreign substances in the eye, intracranial vascular clips, surgery within 6 weeks of entry into the study, coronary stent implanted within 8 weeks prior to the time of the intended MRI, etc).
  4. Known presence of other neurological disorders which may mimic MS including but not limited to: neuromeylitis optica, Lyme disease, untreated vitamin B12 deficiency, neurosarcoidosis and cerebrovascular disorders.
  5. Pregnancy or lactation.
  6. Any concomitant disease that may require chronic treatment with systemic or during the course of the study.
  7. History or currently active primary or secondary immunodeficiency.
  8. Lack of peripheral venous access.
  9. History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies.
  10. Significant or uncontrolled somatic disease or any other significant disease that may preclude patient from participating in the study such as Congestive heart failure ( III or IV functional severity).
  11. Known active bacterial, viral, fungal, mycobacterial infection or other infection, excluding fungal infection of nail beds.
  12. Infection requiring hospitalization or treatment with I.V. antibiotics within 4 weeks prior to baseline visit or oral antibiotics within 2 weeks prior to baseline visit.
  13. History or known presence of recurrent or chronic infection (e.g., or C, ).
  14. History of progressive multifocal leukoencephalopathy (PML)
  15. History of , including solid tumors and hematological malignancies, except basal cell carcinoma, in situ squamous cell carcinoma of the skin, and in situ carcinoma of the cervix of the uterus that have been previously completely excised with documented, clear margins.
  16. History of alcohol or drug abuse within 24 weeks prior to baseline.
  17. History or laboratory evidence of coagulation disorders.
  18. Receipt of a (BCG, MMR, VZV, polio, yellow fever and some influenza vaccine) within 6 weeks prior to baseline. In rare cases when patient requires vaccination with a live vaccine, the screening period may be extended but cannot exceed 8 weeks.
  19. Treatment with any agent within 24 weeks of screening (Visit 1) or five half-lives of the investigational drug (whichever is longer).
  20. Contraindications to or intolerance of oral or i.v. corticosteroids, including methylprednisolone administered i.v.
  21. Treatment with dalfampridine unless on stable dose for ≥ 30 days prior to screening. Patients should remain on stable doses throughout the 48 weeks' treatment period.
  22. Previous treatment with B-cell targeted therapies (i.e. rituximab, ocrelizumab, atacicept, belimumab or ofatumumab).
  23. Systemic corticosteroid therapy within 4 weeks prior to screening.
  24. Any previous treatment with anti-CD4, cladribine, mitoxantrone, daclizumab, teriflunomide, laquinimod, total body irradiation or bone marrow transplantation.
  25. Treatment with cyclophosphamide, azathioprine, mycophenolate mofetil (MMF), cyclosporine, methotrexate or natalizumab within 24 months prior to screening. Patients previously treated with natalizumab will be eligible for this study only if duration of treatment with natalizumab was \< 1 year.
  26. Treatment with fingolimod or dimethyl fumarate (DMF) within 4 weeks prior to screening. Only patients with T lymphocyte count ≥ LLN will be eligible for this study.
  27. Treatment with I.V. immunoglobulin within 12 weeks prior to baseline.
  28. Positive serum β hCG measured at screening.
  29. Positive screening tests for hepatitis B
  30. \< 300/μL.
  31. /SGOT or ALT/SGPT ≥ 2.0 (ULN).
  32. count \<100,000/μL (\<100 x 109/L).
  33. Levels of serum IgG 18% below the LLN.
  34. Levels of serum IgM 8% below the LLN.
  35. Total \<1.5 x 10\^3/μL.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
170 participants (actual)

Study arms

  • Experimental
    Ocrelizumab (CinnaGen, Iran)

    Ocrelizumab (CinnaGen, Iran) 600 mg (given as dual infusions of ocrelizumab 300 mg on Days 1 and 15 of the first 24-week treatment cycle and as single infusions of 600 mg on Day 1 for each 24-week treatment cycle, thereafter) every 24 weeks.

    Biological: Ocrelizumab (CinnaGen, Iran)

  • Active comparator
    Ocrelizumab (Roche, Switzerland)

    Ocrelizumab (Roche, Switzerland) 600 mg (given as dual infusions of ocrelizumab 300 mg on Days 1 and 15 of the first 24-week treatment cycle and as single infusions of 600 mg on Day 1 for each 24-week treatment cycle, thereafter) every 24 weeks.

    Biological: Ocrelizumab (Roche, Switzerland)

Interventions

06

What researchers measure

Primary outcomes

  1. Annualized Relapse Rate at 48 weeks

    Total number of confirmed relapses divided by the total number of days on study A relapse is defined as the appearance of a new or worsening of a previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding relapse. The abnormality must be present for at least 24 hours and occur in the absence of fever or infection

    Time frame: 48 weeks

Secondary outcomes

  1. Time to onset of sustained disability progression for at least 12 weeks

    Disability progression is defined as an increase in the Expanded Disability Status Scale (EDSS) score of: A) At least a 1.5-point increase in patients with a baseline score of 0 B) At least a 1.0-point increase on the EDSS in patients with a baseline score of 0\<EDSS≤5.5 C) At least a 0.5-point increase on the EDSS in patients with a baseline score of \>5.5 The EDSS scale ranges from 0 (normal neurological exam) to 10 (death due to multiple sclerosis)

    Time frame: Baseline up to Week 96

  2. Time to onset of sustained disability progression for at least 24 weeks

    Disability progression is defined as an increase in the Expanded Disability Status Scale (EDSS) score of: A) At least a 1.5-point increase in patients with a baseline score of 0 B) At least a 1.0-point increase on the EDSS in patients with a baseline score of 0\<EDSS≤5.5 C) At least a 0.5-point increase on the EDSS in patients with a baseline score of \>5.5 The EDSS scale ranges from 0 (normal neurological exam) to 10 (death due to multiple sclerosis)

    Time frame: Baseline up to Week 96

  3. Proportion of relapse-free patients by 96 weeks

    A relapse is defined as the appearance of a new or worsening of a previously stable or improving pre-existing neurological abnormality, separated by at least 30 days from onset of a preceding relapse. The abnormality must be present for at least 24 hours and occur in the absence of fever or infection

    Time frame: Week 96

  4. Total number of new Gadolinium (Gd)-enhancing lesions as detected by brain MRI

    Sum of the individual number of (Gd)-enhancing lesions at Weeks 24, 48, and 96

    Time frame: Baseline up to Week 96

  5. Total number of new, and/or enlarging T2 hyperintense lesions as detected by brain MRI

    Sum of the individual number of new, and/or enlarging T2 hyperintense lesions at Weeks 24, 48, and 96

    Time frame: Baseline up to Week 96

  6. Change in total T2 lesion volume as detected by brain MRI from baseline to week 96

    Time frame: Baseline up to Week 96

  7. Number of Participants With Adverse Events (AEs)

    Intensity, seriousness and causality assessment of observed AEs, and abnormal laboratory findings every 12 weeks.

    Time frame: Baseline up to Week 96

  8. Number of Participants With Infusion Related Reactions (IRRs)

    Assessment of IRRs every 24 weeks

    Time frame: Baseline up to Week 96

  9. Immunogenicity Assessment

    Number of participants positive for anti-drug antibodies at weeks 24, 48 and 96

    Time frame: Baseline up to Week 96

07

Study locations

15 sites
  • Qaem International Hospital
    Rasht, Guilan, Iran, Islamic Republic of
  • Qaem Hospital
    Mashhad, Khorasan Razavi, Iran, Islamic Republic of
  • Golestan Hospital
    Ahvaz, Khozestan, Iran, Islamic Republic of
  • Bouali Hospital, MS Clinic
    Sari, Mazandaran, Iran, Islamic Republic of
  • Sina Hospital
    Hamadān, Iran, Islamic Republic of
  • Ayatollah Kashani Hospital, MS Clinic
    Isfahan, Iran, Islamic Republic of
  • Imam Reza Hospital
    Kermanshah, Iran, Islamic Republic of
  • Shafa Hospital
    Kerman, Iran, Islamic Republic of
  • Dr. Nikseresht's office
    Shiraz, Iran, Islamic Republic of
  • Namazi Hospital
    Shiraz, Iran, Islamic Republic of
  • Imam Reza Hospital Department of Neurology
    Tabriz, Iran, Islamic Republic of
  • Amir Alam Hospital
    Tehran, Iran, Islamic Republic of
  • Imam Hossein Hospital, MS Clinic
    Tehran, Iran, Islamic Republic of
  • Imam Khomeini Hospital
    Tehran, Iran, Islamic Republic of
  • Sina Hospital, MS Research Center
    Tehran, Iran, Islamic Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2019 to primary completion in Nov 2020, 14 months.

Of 71 industry-sponsored phase 3 interventional studies under Multiple Sclerosis, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 54. This study's 14 months is below that.

Counting every sponsor, half of 96 studies reached it within 42 months; a quarter within 26 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2021
First posted
Jul 19, 2021
StartActual
Aug 19, 2019
Primary completionActual
Nov 9, 2020
CompletionActual
Oct 1, 2021
Last update
Oct 18, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 18, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04966338
Lead sponsor
Cinnagen
Responsible party
Sponsor
First posted
Jul 19, 2021
Start date
Aug 19, 2019
Primary completion
Nov 9, 2020
Completion
Oct 1, 2021
Last update
Oct 18, 2022

Study contacts

Mohammad Ali Sahraian, professor
principal investigator · Neurologist/MS Research Center, Neuroscience Institute ,Tehran University of Medical Sciences

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ocrelizumab

Start the discussion